From a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...

Even in small villages with a population of less than 1,000, where certain remedies including cough syrups were allowed to be sold without ...

India and Slovakia elevate ties to a comprehensive partnership. A rival tutor accuses Khan Sir of murder. Delhi census Phase 1 records over...

India's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...

Dabur India shares are set to be in focus after the US FDA issued an import alert on drugs manufactured at its Silvassa plant, citing data ...

India is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...

India's drug pricing authority has approved a 50% price hike for essential anti-cancer drugs carboplatin and cisplatin. This decision follo...

The US Food and Drug Administration has placed Dabur India's factory on an import alert. This action follows an inspection that revealed si...

India has seen a significant rise in Foreign Direct Investment, attracting USD 843 billion between 2014-15 and 2025-26. Key government init...

The government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...

Uzbekistan is inviting Indian drug companies to invest more. They are offering better subsidies and technology help. This aims to make Uzbe...

India's top drug regulator is cracking down on veterinary shops. This action follows a significant rejection of shrimp exports to major mar...

India's drug regulator, CDSCO, has mandated all drug companies to establish systems for tracking adverse drug reactions. This move comes am...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

Pharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

The U.S. FDA has identified significant data integrity and manufacturing lapses at a Dabur India plant following a January inspection. Find...